Portal de Periódicos da CAPES

First Face Composite-Tissue Transplant Recipient Successfully Treated for Cytomegalovirus Infection with Preemptive Valganciclovir Treatment

2011; American Society for Microbiology; Volume: 55; Issue: 12 Linguagem: Inglês

10.1128/aac.05335-11

1098-6596

Omar J. BenMarzouk‐Hidalgo, Elisa Cordero, Tomás Gómez‐Cía, María de la Paz Sánchez, J.D. González-Padilla, Pedro Infante-Cossío, Domingo Sicilia‐Castro, Jose-Maria Hernandez-Guisado, Pilar Pérez‐Romero,

Herpesvirus Infections and Treatments

Little is known about cytomegalovirus (CMV) infection after face transplantation, since only two of the 11 cases of face transplantation reported worldwide have documented a CMV infection after transplantation. Herein, we present the first report of a composite-tissue face allotransplant recipient at high risk for CMV infection (D(+)/R(-) [CMV serpositive donor positive/CMV seronegative receptor]) undergoing preemptive treatment. Preemptive treatment was safe and effective for controlling CMV infection and thus promoting early acquisition of a CMV-specific immune response that protected the patient from late-onset CMV disease.